SCHEMBL145533

SCHEMBL145533

COc1cc(CO)cc(OC)c1CCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
ALOX15 P16050 1/20 0.50
APP P05067 1/20 0.43
FFAR1 O14842 4/20 0.43
FFAR4 Q5NUL3 1/20 0.43
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
NFKB1 P19838 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALOX5 P09917 2/20 0.42
POLB P06746 1/20 0.41
LTB4R Q15722 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
LMNA P02545 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
GPR17 Q13304 1/20 0.40
OR51E2 Q9H255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29140671 0.82 ALDH1A1 (0.46) TSHRHSD17B10FFAR1FFAR4ALDH1A1
SCHEMBL4257732 0.82 POLB (0.50) HSD17B10APPFFAR1FFAR4ALDH1A1
SCHEMBL491024 0.82 POLB (0.50) HSD17B10FFAR1ALDH1A1POLBKDM4E
SCHEMBL918362 0.78 HMGCR (0.44) TSHRHSD17B10ALOX15APPALDH1A1
SCHEMBL3361677 0.78 APP (0.55) TSHRHSD17B10ALOX15APPALDH1A1
SCHEMBL146097 0.78 ALDH1A1 (0.47) TSHRFFAR1ALDH1A1TDP1POLB
SCHEMBL147353 0.77 TNKS2 (0.56) TSHRHSD17B10ALOX15APPALDH1A1
SCHEMBL1856540 0.77 NPSR1 (0.52) FFAR1FFAR4GAAGPR17
SCHEMBL28797366 0.76 POLB (0.41) HSD17B10FFAR1FFAR4ALDH1A1POLB
SCHEMBL490990 0.75 ALOX5 (0.69) TSHRFFAR1FFAR4ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107252429-B Novel anti-inflammatory agent 雷斯韦洛吉克斯公司 2023-06-16 CN disclosed
EP-3431086-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2020-06-17 EP disclosed
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2020-04-30 US disclosed
EP-3431086-A1 NOVEL ANTI-INFLAMMATORY AGENTS Resverlogix Corp. (CA) 2019-01-23 EP disclosed
EP-2421533-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2018-10-17 EP disclosed
US-20170333419-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2017-11-23 US disclosed
US-20170326143-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2017-11-16 US disclosed
CN-107252429-A New antiinflammatory 雷斯韦洛吉克斯公司 2017-10-17 CN disclosed
US-9757368-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2017-09-12 US disclosed
CN-102458405-B Novel anti-inflammatory agents 雷斯韦洛吉克斯公司 2017-06-23 CN disclosed
WO-2013186612-A1 THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS RVX THERAPEUTICS INC. (CA) 2013-12-19 WO disclosed
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed
CN-102458405-A Novel anti-inflammatory agents RESVERLOGIX CORP 2012-05-16 CN disclosed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 US disclosed
EP-2421533-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-02-29 EP disclosed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TSHR 4123/4885HSD17B10 4159/4885ALOX15 265/4885
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 TSHR 3086/4885HSD17B10 2976/4885ALOX15 3873/4885
US-20170326143-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TSHR 4123/4885HSD17B10 4159/4885ALOX15 265/4885
US-20170333419-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TSHR 4123/4885HSD17B10 4159/4885ALOX15 265/4885
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TSHR 4123/4885HSD17B10 4159/4885ALOX15 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.